Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...
The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription ...
For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...
Capital Market on MSN
Glenmark gains after launching first-ever nebulized triple therapy for COPD
The therapies combine three proven medicines-Glycopyrronium, Formoterol, and Budesonide-to reduce airway obstruction, control ...
In 2024, drugmakers delivered breakthrough treatments in conditions that had seen little progress for decades—and helped make existing therapies more accessible. Approved in July, Eli Lilly’s Kisunla ...
The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...
SNS Insider Reports Steady Growth of the U.S. Asthma and COPD Drugs Market from USD 8.56 Billion in 2025E to USD 12.68 Billion by 2033, Supported by Awareness Programs, Expanding Biologic Usage, and ...
On World COPD Day, experts highlight that while COPD is treatable, it can't be reversed; awareness and prevention are crucial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback